Carregant...

A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma

Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death (PD)-1 receptor. Common cutaneous adverse side effects of PD-1 inhibitors include maculopapular rash, pruritus, vitiligo, and lichenoid skin and mucosal reactions. Here, we describe a man in his sixties with metas...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Dermatol
Autors principals: Wolner, Z.J., Marghoob, A.A., Pulitzer, M.P., Postow, M.A., Marchetti, M.A.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5533648/
https://ncbi.nlm.nih.gov/pubmed/28132411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.15354
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!